Market capitalization | $2.55m |
Enterprise Value | $1.63m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.22 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-6.05m |
Free Cash Flow (TTM) Free Cash Flow | $-5.16m |
Cash position | $920.00k |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
1 Analyst has issued a forecast Protagenic Therapeutics Inc:
1 Analyst has issued a forecast Protagenic Therapeutics Inc:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.05 -0.05 |
-
|
|
EBITDA | -6 -6 |
73%
73%
|
EBIT (Operating Income) EBIT | -6.05 -6.05 |
75%
75%
|
Net Profit | -6.40 -6.40 |
86%
86%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Protagenic Therapeutics, Inc. is a biotechnology company, which engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It offers the PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.
Head office | United States |
Employees | 3 |
Founded | 1994 |
Website | www.protagenic.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.